Baxter International has signed an agreement to acquire Somatogen in a stock merger worth an estimated $189 million. Somatogen is developing recombinant haemoglobin products and the acquisition will add to Baxter's expertise in the field of oxygen-carrying "blood substitutes".
Baxter International has signed an agreement to acquire Somatogen in a stock merger worth an estimated $189 million. Somatogen is developing recombinant haemoglobin products and the acquisition will add to Baxter's expertise in the field of oxygen-carrying "blood substitutes".
Baxter is offering $9 per Somatogen share in Baxter stock, plus a cash milestone of up to $2 per share...
Create an account to read this article
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.
Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
